MedTrace Logo

Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers

NCT03012828 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2019-03-14

Study results available
· View outcomes & findings →

Summary

This study will investigate the effect of a single oral dose of moxidectin on the QT interval associated with moxidectin plasma concentrations.

The effect of moxidectin on other ECG intervals, and on safety, will also be assessed, as will preliminary pharmacokinetics and metabolism

Conditions

  • QT Effects in Healthy Volunteers

Interventions

DRUG

Moxidectin

Moxidectin is a broad spectrum macrocyclic lactone endectocide

OTHER

Placebo

Sponsors & Collaborators

  • Medicines Development for Global Health

    lead OTHER

Principal Investigators

  • Mark Sullivan · Sponsor GmbH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2017-03-31
Completion
2017-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03012828 on ClinicalTrials.gov